Display options
Cite
Fujimori N, Tanaka N, Shibata S, et al. Controlled attenuation parameter is correlated with actual hepatic fat content in patients with non-alcoholic fatty liver disease with none-to-mild obesity and liver fibrosis. Hepatol Res. 2016;46(10):1019-27doi: 10.1111/hepr.12649.
Fujimori, N., Tanaka, N., Shibata, S., Sano, K., Yamazaki, T., Sekiguchi, T., Kitabatake, H., Ichikawa, Y., Kimura, T., Komatsu, M., Umemura, T., Matsumoto, A., & Tanaka, E. (2016). Controlled attenuation parameter is correlated with actual hepatic fat content in patients with non-alcoholic fatty liver disease with none-to-mild obesity and liver fibrosis. Hepatology research : the official journal of the Japan Society of Hepatology, 46(10), 1019-27. https://doi.org/10.1111/hepr.12649
Fujimori, Naoyuki, et al. "Controlled attenuation parameter is correlated with actual hepatic fat content in patients with non-alcoholic fatty liver disease with none-to-mild obesity and liver fibrosis." Hepatology research : the official journal of the Japan Society of Hepatology vol. 46,10 (2016): 1019-27. doi: https://doi.org/10.1111/hepr.12649
Fujimori N, Tanaka N, Shibata S, Sano K, Yamazaki T, Sekiguchi T, Kitabatake H, Ichikawa Y, Kimura T, Komatsu M, Umemura T, Matsumoto A, Tanaka E. Controlled attenuation parameter is correlated with actual hepatic fat content in patients with non-alcoholic fatty liver disease with none-to-mild obesity and liver fibrosis. Hepatol Res. 2016 Sep;46(10):1019-27. doi: 10.1111/hepr.12649. Epub 2016 Mar 15. PMID: 27183219.
Copy Download .nbib Format: NLM
Share it on

Hepatol Res. 2016 Sep;46(10):1019-27. doi: 10.1111/hepr.12649. Epub 2016 Mar 15.

Controlled attenuation parameter is correlated with actual hepatic fat content in patients with non-alcoholic fatty liver disease with none-to-mild obesity and liver fibrosis.

Hepatology research : the official journal of the Japan Society of Hepatology

Naoyuki Fujimori, Naoki Tanaka, Soichiro Shibata, Kenji Sano, Tomoo Yamazaki, Tomohiro Sekiguchi, Hiroyuki Kitabatake, Yuki Ichikawa, Takefumi Kimura, Michiharu Komatsu, Takeji Umemura, Akihiro Matsumoto, Eiji Tanaka

Affiliations

  1. Department of Internal Medicine, Division of Gastroenterology, Shinshu University School of Medicine, Matsumoto, Japan.
  2. Department of Metabolic Regulation, Shinshu University Graduate School of Medicine, Matsumoto, Japan.
  3. Department of Laboratory Medicine, Shinshu University Hospital, Matsumoto, Japan.

PMID: 27183219 DOI: 10.1111/hepr.12649

Abstract

AIM: Non-invasive steatosis-quantifying methods are required for non-alcoholic fatty liver disease (NAFLD) patients in order to monitor disease severity and assess therapeutic efficacy. Controlled attenuation parameter (CAP) evaluated with vibration-controlled transient elastography can predict the presence of steatosis, but its application to absolute hepatic fat quantitation remains unclear. The aim of this st\udy was to examine whether CAP is correlated with real hepatic fat content in NAFLD patients.

METHODS: Eighty-two NAFLD patients who had undergone percutaneous liver biopsy were enrolled. CAP was measured using FibroScan(®) just before liver biopsy. The percentage of fat droplet area to hepatocyte area in biopsied specimen was determined morphometrically using computerized optical image analyzing system. The correlation between CAP and liver histology was examined.

RESULTS: CAP showed an excellent correlation with actual liver fat percentage in the NAFLD patients with body mass index (BMI) of less than 28 kg/m(2) (r = 0.579, P < 0.0001), especially less than 25 kg/m(2) (r = 0.708, P < 0.01), but the meaningful correlation disappeared in the patients with BMI of 28 kg/m(2) or more. In the patients with BMI of less than 28 kg/m(2) , CAP quantitativeness was affected by the presence of stage 2-4 fibrosis, but not the presence of hepatocyte ballooning and severity of lobular inflammation.

CONCLUSION: CAP may be a promising tool for quantifying hepatic fat content in NAFLD patients with none-to-mild obesity and liver fibrosis. Further improvement of CAP performance is needed for the NAFLD patients with BMI of more than 28 kg/m(2) or significant hepatic fibrosis.

© 2016 The Japan Society of Hepatology.

Keywords: body mass index; controlled attenuation parameter; fibrosis; liver fat; non-alcoholic fatty liver disease

Publication Types